Anti-Coagulants - Finland

Finland

The revenue in the Anti-Coagulants market in Finland is projected to reach US$62.39m in 2024.
It is expected to show an annual growth rate (CAGR 2024-2028) of 7.39%, resulting in a market volume of US$82.98m by 2028.
In global comparison, United States will generate the most revenue, with US$16,740.00m in 2024.
In Finland, the demand for novel oral anticoagulants (NOACs) is on the rise, as patients seek more convenient and effective alternatives to traditional warfarin therapy.

Key regions: Germany, South Korea, France, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Finland has seen significant growth in recent years.

Customer preferences: Patients in Finland have shown a growing preference for Anti-Coagulants due to their effectiveness in treating a range of conditions. The aging population in Finland has also contributed to the growth of the Anti-Coagulants market, as older individuals are more likely to require treatment for conditions such as atrial fibrillation and deep vein thrombosis.

Trends in the market: One trend in the Anti-Coagulants market in Finland is the increasing use of direct oral anticoagulants (DOACs) over traditional Vitamin K antagonists (VKAs). DOACs are more convenient for patients as they do not require frequent monitoring and have fewer drug interactions. Additionally, DOACs have been shown to have a lower risk of major bleeding compared to VKAs.Another trend in the market is the rise of biosimilars, which are lower-cost alternatives to brand-name Anti-Coagulants. Biosimilars have been shown to be just as safe and effective as their brand-name counterparts, and are increasingly being prescribed by healthcare providers in Finland.

Local special circumstances: The Finnish healthcare system is publicly funded, which means that patients have access to Anti-Coagulants at little or no cost. This has contributed to the high usage of Anti-Coagulants in Finland, as patients are more likely to seek treatment when it is affordable.

Underlying macroeconomic factors: The Finnish economy has been relatively stable in recent years, which has allowed for increased investment in healthcare infrastructure and research. This has led to the development of new Anti-Coagulants and treatment options, which has in turn contributed to the growth of the Anti-Coagulants market in Finland. Additionally, the high level of healthcare spending in Finland has ensured that patients have access to the latest treatments and technologies.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.